Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.

2018
Purpose To analyse safety and efficacy of treatment based on ombitasvir/paritaprevir/ritonavir/ dasabuvirplus ribavirinin the sub-group of GT1 patients older than 65 years.
    • Correction
    • Source
    • Cite
    • Save
    21
    References
    6
    Citations
    NaN
    KQI
    []
    Baidu
    map